Impact of metabolic syndrome on oncologic outcome after radical gastrectomy for gastric cancer

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 3, 2014, Pages 372-378

  Kim, Eun Hye ^a   Lee, Hyuk ^a   Chung, Hyunsoo ^a   Park, Jun Chul ^a   Shin, Sung Kwan ^a   Lee, Sang Kil ^a   Hyung, Woo Jin ^a   Lee, Yong Chan ^a   Noh, Sung Hoon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OVERALL SURVIVAL; RADICAL GASTRECTOMY; RISK FACTOR; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TUMOR RECURRENCE; ADENOCARCINOMA; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; PROGNOSIS; SOUTH KOREA; STOMACH NEOPLASMS;

ADENOCARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REPUBLIC OF KOREA; STOMACH NEOPLASMS;

EID: 84902505818     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.11.009     Document Type: Article

References (42)

1. Park J.H., Lee K.S., Choi K.S. Burden of cancer in Korea during 2000-2020. Cancer Epidemiol 2013.
2. Jaggers J.R., Sui X., Hooker S.P., LaMonte M.J., Matthews C.E., Hand G.A., et al. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer 2009, 45:1831-1838.
3. Kim J.H., Lim Y.J., Kim Y.H., Sung I.K., Shim S.G., Oh S.O., et al. Is metabolic syndrome a risk factor for colorectal adenoma?. Cancer Epidemiol Biomarkers Prev 2007, 16:1543-1546.
4. Sturmer T., Buring J.E., Lee I.M., Gaziano J.M., Glynn R.J. Metabolic abnormalities and risk for colorectal cancer in the physicians' health study. Cancer Epidemiol Biomarkers Prev 2006, 15:2391-2397.
5. Ahmed R.L., Schmitz K.H., Anderson K.E., Rosamond W.D., Folsom A.R. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006, 107:28-36.
6. Bowers K., Albanes D., Limburg P., Pietinen P., Taylor P.R., Virtamo J., et al. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 2006, 164:652-664.
7. Colangelo L.A., Gapstur S.M., Gann P.H., Dyer A.R., Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 2002, 11:385-391.
8. Trevisan M., Liu J., Muti P., Misciagna G., Menotti A., Fucci F. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 2001, 10:937-941.
9. Patel A.V., Rodriguez C., Bernstein L., Chao A., Thun M.J., Calle E.E. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S Cohort. Cancer Epidemiol Biomarkers Prev 2005, 14:459-466.
10. Berrington de Gonzalez A., Spencer E.A., Bueno-de-Mesquita H.B., Roddam A., Stolzenberg-Solomon R., Halkjaer J., et al. Anthropometry, physical activity, and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2006, 15:879-885.
11. Stolzenberg-Solomon R.Z., Graubard B.I., Chari S., Limburg P., Taylor P.R., Virtamo J., et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005, 294:2872-2878.
12. Bowker S.L., Johnson J.A. Prospective study of hyperglycemia and cancer risk: response to Stattin et al. Diabetes Care 2007, 30:e77. [author reply e78].
13. Jung M.K., Jeon S.W., Cho C.M., Tak W.Y., Kweon Y.O., Kim S.K., et al. Hyperglycaemia, hypercholesterolaemia and the risk for developing gastric dysplasia. Dig Liver Dis 2008, 40:361-365.
14. Inoue M., Iwasaki M., Otani T., Sasazuki S., Noda M., Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006, 166:1871-1877.
15. Lee J.S., Cho S.I., Park H.S. Metabolic syndrome and cancer-related mortality among Korean men and women. Ann Oncol 2010, 21:640-645.
16. Castillejos-Molina R., Rodriguez-Covarrubias F., Sotomayor M., Gomez-Alvarado M.O., Villalobos-Gollas M., Gabilondo F., et al. Impact of metabolic syndrome on biochemical recurrence of prostate cancer after radical prostatectomy. Urol Int 2011, 87:270-275.
17. Corley D.A., Kubo A., Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev 2008, 17:352-358.
18. Paller C.J., Antonarakis E.S. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol 2013, 11:14-23.
19. Park S.M., Lim M.K., Shin S.A., Yun Y.H. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol 2006, 24:5017-5024.
20. Pasanisi P., Berrino F., De Petris M., Venturelli E., Mastroianni A., Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006, 119:236-238.
21. Shen Z., Ye Y., Bin L., Yin M., Yang X., Jiang K., et al. Metabolic syndrome is an important factor for the evolution of prognosis of colorectal cancer: survival, recurrence, and liver metastasis. Am J Surg 2010, 200:59-63.
22. WHO Expert Consultation Appropriate body-mass index for Asian populations and its implications for policy and intervention, strategies. Lancet 2004, 363:157-163.
23. Popkin B.M., Adair L.S., Ng S.W. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev 2012, 70:3-21.
24. Matthews C.E., Sui X., LaMonte M.J., Adams S.A., Hebert J.R., Blair S.N. Metabolic syndrome and risk of death from cancers of the digestive system. Metabolism 2010, 59:1231-1239.
25. Landman G.W., Ubink-Veltmaat L.J., Kleefstra N., Kollen B.J., Bilo H.J. Increased cancer mortality in type 2 diabetes (ZODIAC-3). Anticancer Res 2008, 28:1373-1375.
26. Arends J. Metabolism in cancer patients. Anticancer Res 2010, 30:1863-1868.
27. Rosmorduc O., Fartoux L. HCC and NASH: how strong is the clinical demonstration?. Clin Res Hepatol Gastroenterol 2012, 36:202-208.
28. Landman G.W., Van Hateren K.J., Kleefstra N., Bilo H.J. The relationship between obesity and cancer mortality in type 2 diabetes: a ten-year follow-up study (ZODIAC-21). Anticancer Res 2010, 30:681-682.
29. Yamagata H., Kiyohara Y., Nakamura S., Kubo M., Tanizaki Y., Matsumoto T., et al. Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the Hisayama study. Diabetes Care 2005, 28:789-794.
30. Stocks T., Rapp K., Bjorge T., Manjer J., Ulmer H., Selmer R., et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 2009, 6:e1000201.
31. Ikeda F., Doi Y., Yonemoto K., Ninomiya T., Kubo M., Shikata K., et al. Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology 2009, 136:1234-1241.
32. Min Y.W., Yun H.S., Chang W.I., Kim J.Y., Kim Y.H., Son H.J., et al. Influence of non-alcoholic fatty liver disease on the prognosis in patients with colorectal cancer. Clin Res Hepatol Gastroenterol 2012, 36:78-83.
33. Samani A.A., Yakar S., LeRoith D., Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007, 28:20-47.
34. Donohoe C.L., Pidgeon G.P., Lysaght J., Reynolds J.V. Obesity gastrointestinal cancer. Br J Surg 2010, 97:628-642.
35. Knekt P., Reunanen A., Aromaa A., Heliovaara M., Hakulinen T., Hakama M. Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol 1988, 41:519-530.
36. Asano K., Kubo M., Yonemoto K., Doi Y., Ninomiya T., Tanizaki Y., et al. Impact of serum total cholesterol on the incidence of gastric cancer in a population-based prospective study: the Hisayama study. Int J Cancer 2008, 122:909-914.
37. Iso H., Ikeda A., Inoue M., Sato S., Tsugane S. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer 2009, 125:2679-2686.
38. Ahn J., Lim U., Weinstein S.J., Schatzkin A., Hayes R.B., Virtamo J., et al. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:2814-2821.
39. Platz E.A., Till C., Goodman P.J., Parnes H.L., Figg W.D., Albanes D., et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2009, 18:2807-2813.
40. Tornberg S.A., Carstensen J.M., Holm L.E. Risk of stomach cancer in association with serum cholesterol and beta-lipoprotein. Acta Oncol 1988, 27:39-42.
41. Kritchevsky S.B., Wilcosky T.C., Morris D.L., Truong K.N., Tyroler H.A. Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Cancer Res 1991, 51:3198-3203.
42. Sorlie P.D., Feinleib M. The serum cholesterol-cancer relationship: an analysis of time trends in the Framingham Study. J Natl Cancer Inst 1982, 69:989-996.